Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Novartis gets approval to sell Kymriah in Japan for $306,000

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 04:29am EDT
FILE PHOTO: FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel

TOKYO (Reuters) - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis' cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.

The one-time, personalised therapy, which was approved in Japan in March, will be available in the country for young people with acute lymphoblastic leukaemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

The so-called CAR-T therapy, which Novartis believes could treat up to 216 Japanese patients a year, potentially generating annual sales of 7.2 billion yen ($65.7 million), has been a hailed as a revolutionary, last-ditch hope for people whose cancer advanced after previous treatment.

But the Basel-based drugmaker has faced U.S. hurdles, largely for DLBCL patients, where challenges meeting commercial specifications have forced it to give some product away for free. Expanding to Japan, plus ongoing efforts to resolve the U.S. problems, are part of Chief Executive Vas Narasimhan's goal of turning Kymriah into $1 billion-per-year seller.

The U.S. specification hiccup is not an issue in Japan, a spokesman said.

"Our cell viability commercial specifications in the EU, Switzerland, Australia, Canada and Japan are now aligned with those from our clinical trials," the spokesman said. "We intend to continue to engage with the (U.S. Food and Drug Administration) to change our commercial viability specifications in the United States."

While the impasse has been a "disappointment," Novartis added its scientists had recorded comparable safety and efficacy even with Kymriah that doesn't meet FDA specifications.

"We continue to optimize our process and make incremental gains as we work toward our ultimate goal of providing this transformative product to patients in both indications, and have been able to deliver Kymriah to the majority of patients," the company said.

Kymriah works by removing disease fighting T-cells from patients, modifying them to attack cancer, and re-infusing them back into the patients.

The therapy belongs to a slate of advanced, costly therapies including gene therapy and cancer-fighting nuclear medicine that Narasimhan has either developed or bought via acquisitions as he maps out Novartis's future.

For U.S. patients, Kymriah costs $475,000 for those with ALL and $373,000 for DLBCL.

Global sales of Kymriah were $76 million in 2018, putting it well outside Novartis's top 20 medications. It's also shy of Gilead Sciences' Yescarta, another CAR-T therapy that last year posted $264 million in sales but which also missed analyst expectations.

(Reporting by Takashi Umekawa; Additional reporting by John Miller in Zurich; Editing by Muralikumar Anantharaman and Mark Potter)

By Takashi Umekawa

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 0.44% 66.17 Delayed Quote.5.79%
NOVARTIS 0.06% 85.9 Delayed Quote.16.65%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.11% 108.209 Delayed Quote.-1.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/16A Plan to Fight Hep C -- WSJ
DJ
09/12GILEAD SCIENCES : Ex-dividend day for
FA
09/09GILEAD SCIENCES : and the Elton John AIDS Foundation Launch RADIAN Initiative to..
BU
08/29GILEAD SCIENCES : An amendment to a SC 13D filing
PU
08/29AGENUS : Triggers 3rd Milestone in its Collaboration with Gilead
AQ
08/29GILEAD SCIENCES : Report
CO
08/27GILEAD SCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/26GILEAD SCIENCES : to Present at the Morgan Stanley Global Healthcare Conference ..
BU
08/26GILEAD SCIENCES : Alberta Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/26GILEAD SCIENCES : And galapagos complete closing of their transformative researc..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 272 M
Debt 2019 3 023 M
Yield 2019 3,81%
P/E ratio 2019 18,9x
P/E ratio 2020 11,6x
EV / Sales2019 3,89x
EV / Sales2020 3,75x
Capitalization 83 801 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,52  $
Last Close Price 66,17  $
Spread / Highest target 43,6%
Spread / Average Target 21,7%
Spread / Lowest Target -9,32%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.79%83 801
VERTEX PHARMACEUTICALS6.21%45 637
REGENERON PHARMACEUTICALS-22.86%31 283
GENMAB27.92%13 184
NEUROCRINE BIOSCIENCES, INC.42.01%8 956
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 531